Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep–wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol

INTRODUCTION: Metformin is a medication likely to improve measures of cardiometabolic disturbance in young people with mental illness. Evidence also suggests metformin may improve depressive symptoms. This 52-week double-blind randomised control trial (RCT) aims to investigate the efficacy of metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Chloe, Carpenter, Joanne Sarah, Nichles, Alissa, Zmicerevska, Natalia, Song, Yun Ju Christine, McHugh, Catherine, Hamilton, Blake, Hockey, Samuel, Crouse, Jacob, Koethe, Dagmar, Scott, Elizabeth M, Hickie, Ian B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Mental Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945047/
https://www.ncbi.nlm.nih.gov/pubmed/36810174
http://dx.doi.org/10.1136/bmjopen-2022-064682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945047/
https://www.ncbi.nlm.nih.gov/pubmed/36810174
http://dx.doi.org/10.1136/bmjopen-2022-064682

Ejemplares similares